3.943
price up icon4.31%   0.163
 
loading
Nanobiotix Adr stock is traded at $3.943, with a volume of 14,836. It is up +4.31% in the last 24 hours and down -18.02% over the past month. Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
See More
Previous Close:
$3.78
Open:
$3.78
24h Volume:
14,836
Relative Volume:
1.67
Market Cap:
$192.87M
Revenue:
$27,600
Net Income/Loss:
$-36.04M
P/E Ratio:
-2.2249
EPS:
-1.7722
Net Cash Flow:
$-1.66M
1W Performance:
-2.64%
1M Performance:
-18.02%
6M Performance:
-44.54%
1Y Performance:
-34.28%
1-Day Range:
Value
$3.5733
$4.11
1-Week Range:
Value
$3.5733
$4.2036
52-Week Range:
Value
$3.5733
$8.962

Nanobiotix Adr Stock (NBTX) Company Profile

Name
Name
Nanobiotix Adr
Name
Phone
-
Name
Address
-
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2024-11-10
Name
Latest SEC Filings
Name
NBTX's Discussions on Twitter

Compare NBTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NBTX 4.0685 192.87M 27,600 -36.04M -1.66M -1.7722
VRTX 447.12 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.36 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.00 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.10 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.41 24.49B 3.30B -501.07M 1.03B 11.54

Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-06-21 Initiated Evercore ISI Outperform

Nanobiotix Adr Stock (NBTX) Latest News

pulisher
Nov 12, 2024

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.

Nov 12, 2024
pulisher
Jun 16, 2024

Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World

Jun 16, 2024
pulisher
Jun 15, 2024

Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat

Jun 15, 2024
pulisher
May 24, 2024

Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat

May 24, 2024
pulisher
May 23, 2024

Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com

May 23, 2024
pulisher
May 21, 2024

NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail

May 21, 2024
pulisher
May 16, 2024

Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks

May 16, 2024
pulisher
May 15, 2024

Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks

May 15, 2024
pulisher
May 14, 2024

Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer StudyTipRanks.com - TipRanks

May 14, 2024
pulisher
Apr 26, 2024

Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks

Apr 26, 2024
pulisher
Apr 11, 2024

Nanobiotix Sa ADR Updates Share Capital InfoTipRanks.com - TipRanks

Apr 11, 2024
pulisher
Apr 02, 2024

Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks

Apr 02, 2024
pulisher
Jun 23, 2022

NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 - The Globe and Mail

Jun 23, 2022
pulisher
Oct 24, 2021

NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC ... - The Globe and Mail

Oct 24, 2021
pulisher
Jun 03, 2021

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire

Jun 03, 2021
pulisher
Jun 01, 2021

NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive ... - The Globe and Mail

Jun 01, 2021
pulisher
May 11, 2021

NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire

May 11, 2021
pulisher
Dec 15, 2020

IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet

Dec 15, 2020
pulisher
Dec 11, 2020

NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat

Dec 11, 2020
pulisher
Dec 11, 2020

Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat

Dec 11, 2020
pulisher
Apr 07, 2020

Nanobiotix - Massachusetts Biotechnology Council

Apr 07, 2020

Nanobiotix Adr Stock (NBTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):